Cardiac Pathways gets go-ahead for ablation catheters:
This article was originally published in Clinica
Executive Summary
Cardiac Pathways has received pre-market approval (PMA) for its Chillirpm cooled ablation catheters, including the company's Real-time Position Management navigation technology. The device includes a bi-directional steering capability and integrates the company's ultrasound transducer technology for dynamic real-time catheter navigation and visualisation. The PMA provides the additional approval necessary to use the RPM technology for therapy, the Sunnyvale, California-based company said.
You may also be interested in...
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.
UK MHRA Updates Assistive Tech And Borderline Regulations
Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.